These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 32832010)

  • 1. Ticagrelor Conditioning Effects Are Not Additive to Cardioprotection Induced by Direct NLRP3 Inflammasome Inhibition: Role of RISK, NLRP3, and Redox Cascades.
    Penna C; Aragno M; Cento AS; Femminò S; Russo I; Bello FD; Chiazza F; Collotta D; Alves GF; Bertinaria M; Zicola E; Mercurio V; Medana C; Collino M; Pagliaro P
    Oxid Med Cell Longev; 2020; 2020():9219825. PubMed ID: 32832010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological Inhibition of NLRP3 Inflammasome Attenuates Myocardial Ischemia/Reperfusion Injury by Activation of RISK and Mitochondrial Pathways.
    Mastrocola R; Penna C; Tullio F; Femminò S; Nigro D; Chiazza F; Serpe L; Collotta D; Alloatti G; Cocco M; Bertinaria M; Pagliaro P; Aragno M; Collino M
    Oxid Med Cell Longev; 2016; 2016():5271251. PubMed ID: 28053692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dapagliflozin and Ticagrelor Have Additive Effects on the Attenuation of the Activation of the NLRP3 Inflammasome and the Progression of Diabetic Cardiomyopathy: an AMPK-mTOR Interplay.
    Chen H; Tran D; Yang HC; Nylander S; Birnbaum Y; Ye Y
    Cardiovasc Drugs Ther; 2020 Aug; 34(4):443-461. PubMed ID: 32335797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic Deletion or Pharmacological Inhibition of Soluble Epoxide Hydrolase Ameliorates Cardiac Ischemia/Reperfusion Injury by Attenuating NLRP3 Inflammasome Activation.
    Darwesh AM; Keshavarz-Bahaghighat H; Jamieson KL; Seubert JM
    Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31319469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ticagrelor inhibits the NLRP3 inflammasome to protect against inflammatory disease independent of the P2Y
    Huang B; Qian Y; Xie S; Ye X; Chen H; Chen Z; Zhang L; Xu J; Hu H; Ma S; Héroux P; Wang D; Shen HM; Wu Y; Xia D
    Cell Mol Immunol; 2021 May; 18(5):1278-1289. PubMed ID: 32523112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ticagrelor and Rosuvastatin Have Additive Cardioprotective Effects via Adenosine.
    Birnbaum Y; Birnbaum GD; Birnbaum I; Nylander S; Ye Y
    Cardiovasc Drugs Ther; 2016 Dec; 30(6):539-550. PubMed ID: 27830382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NLRP3 Inflammasome in Cardioprotective Signaling.
    Zuurbier CJ
    J Cardiovasc Pharmacol; 2019 Oct; 74(4):271-275. PubMed ID: 31356546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardioprotective effects of CYP-derived epoxy metabolites of docosahexaenoic acid involve limiting NLRP3 inflammasome activation
    Darwesh AM; Jamieson KL; Wang C; Samokhvalov V; Seubert JM
    Can J Physiol Pharmacol; 2019 Jun; 97(6):544-556. PubMed ID: 30326194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Platelet-Mediated Transfer of Cardioprotection by Remote Ischemic Conditioning and Its Abrogation by Aspirin But Not by Ticagrelor.
    Lieder HR; Tsoumani M; Andreadou I; Schrör K; Heusch G; Kleinbongard P
    Cardiovasc Drugs Ther; 2023 Oct; 37(5):865-876. PubMed ID: 35595877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parkin-Dependent Mitophagy is Required for the Inhibition of ATF4 on NLRP3 Inflammasome Activation in Cerebral Ischemia-Reperfusion Injury in Rats.
    He Q; Li Z; Meng C; Wu J; Zhao Y; Zhao J
    Cells; 2019 Aug; 8(8):. PubMed ID: 31416289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel NLRP3 inhibitor INF195: Low doses provide effective protection against myocardial ischemia/reperfusion injury.
    Gastaldi S; Giordano M; Blua F; Rubeo C; Boscaro V; Femminò S; Comità S; Gianquinto E; Landolfi V; Marini E; Gallicchio M; Spyrakis F; Pagliaro P; Bertinaria M; Penna C
    Vascul Pharmacol; 2024 Sep; 156():107397. PubMed ID: 38897555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Scutellarin protects against myocardial ischemia-reperfusion injury by suppressing NLRP3 inflammasome activation.
    Xu LJ; Chen RC; Ma XY; Zhu Y; Sun GB; Sun XB
    Phytomedicine; 2020 Mar; 68():153169. PubMed ID: 31999976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ticagrelor and Dapagliflozin Have Additive Effects in Ameliorating Diabetic Nephropathy in Mice with Type-2 Diabetes Mellitus.
    Birnbaum Y; Chen H; Tran D; Nylander S; Ye Y
    Cardiovasc Drugs Ther; 2022 Oct; 36(5):829-840. PubMed ID: 34232433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protective Effect of Ethyl Pyruvate against Myocardial Ischemia Reperfusion Injury through Regulations of ROS-Related NLRP3 Inflammasome Activation.
    Jun JH; Shim JK; Oh JE; Shin EJ; Shin E; Kwak YL
    Oxid Med Cell Longev; 2019; 2019():4264580. PubMed ID: 30728885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autophagy Attenuates Angiotensin II-Induced Pulmonary Fibrosis by Inhibiting Redox Imbalance-Mediated NOD-Like Receptor Family Pyrin Domain Containing 3 Inflammasome Activation.
    Meng Y; Pan M; Zheng B; Chen Y; Li W; Yang Q; Zheng Z; Sun N; Zhang Y; Li X
    Antioxid Redox Signal; 2019 Feb; 30(4):520-541. PubMed ID: 29486589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The NLRP3 inflammasome is up-regulated in cardiac fibroblasts and mediates myocardial ischaemia-reperfusion injury.
    Sandanger Ø; Ranheim T; Vinge LE; Bliksøen M; Alfsnes K; Finsen AV; Dahl CP; Askevold ET; Florholmen G; Christensen G; Fitzgerald KA; Lien E; Valen G; Espevik T; Aukrust P; Yndestad A
    Cardiovasc Res; 2013 Jul; 99(1):164-74. PubMed ID: 23580606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metformin protects against myocardial ischemia-reperfusion injury and cell pyroptosis via AMPK/NLRP3 inflammasome pathway.
    Zhang J; Huang L; Shi X; Yang L; Hua F; Ma J; Zhu W; Liu X; Xuan R; Shen Y; Liu J; Lai X; Yu P
    Aging (Albany NY); 2020 Nov; 12(23):24270-24287. PubMed ID: 33232283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Naoxintong attenuates Ischaemia/reperfusion Injury through inhibiting NLRP3 inflammasome activation.
    Wang Y; Yan X; Mi S; Li Z; Wang Y; Zhu H; Sun X; Zhao B; Zhao C; Zou Y; Hu K; Ding X; Sun A; Ge J
    J Cell Mol Med; 2017 Jan; 21(1):4-12. PubMed ID: 27785882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytoprotective activated protein C averts Nlrp3 inflammasome-induced ischemia-reperfusion injury via mTORC1 inhibition.
    Nazir S; Gadi I; Al-Dabet MM; Elwakiel A; Kohli S; Ghosh S; Manoharan J; Ranjan S; Bock F; Braun-Dullaeus RC; Esmon CT; Huber TB; Camerer E; Dockendorff C; Griffin JH; Isermann B; Shahzad K
    Blood; 2017 Dec; 130(24):2664-2677. PubMed ID: 28882883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Matrix metalloproteinase-2 proteolyzes mitofusin-2 and impairs mitochondrial function during myocardial ischemia-reperfusion injury.
    Bassiouni W; Valencia R; Mahmud Z; Seubert JM; Schulz R
    Basic Res Cardiol; 2023 Jul; 118(1):29. PubMed ID: 37495895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.